Skip to main content
Top
Published in: Diabetologia 3/2018

Open Access 01-03-2018 | Article

Short-term progression of cardiometabolic risk factors in relation to age at type 2 diabetes diagnosis: a longitudinal observational study of 100,606 individuals from the Swedish National Diabetes Register

Authors: Andri O. Steinarsson, Araz Rawshani, Soffia Gudbjörnsdottir, Stefan Franzén, Ann-Marie Svensson, Naveed Sattar

Published in: Diabetologia | Issue 3/2018

Login to get access

Abstract

Aims/hypothesis

The reasons underlying a greater association of premature mortality with early-onset type 2 diabetes relative to late-onset disease are unclear. We evaluated the clinical characteristics at type 2 diabetes diagnosis and the broad trajectories in cardiometabolic risk factors over the initial years following diagnosis in relation to age at diagnosis.

Methods

Our cohort consisted of 100,606 individuals with newly diagnosed type 2 diabetes enrolled in the Swedish National Diabetes Register from 2002 to 2012. The average follow-up time was 2.8 years. Analyses were performed using a linear mixed-effects model for continuous risk factors and a mixed generalised linear model with a logistic link function for dichotomous risk factors.

Results

The individuals diagnosed at the youngest age (18–44 years) were more often male and had the highest BMI (mean of 33.4 kg/m2) at diagnosis and during follow-up compared with all other groups (those diagnosed at 45–59 years, 60–74 years and ≥75 years; p < 0.05), being ~5 kg/m2 higher than the oldest group. Although HbA1c patterns were similar between all age groups, there was a difference of about 5 mmol/mol (0.45%) between the two groups at 8 years post-diagnosis (p < 0.05). Additionally, individuals diagnosed younger had ~0.7 mmol/l higher triacylglycerol, and ~0.2 mmol/l lower HDL-cholesterol levels at diagnosis relative to the oldest group. Such differences continued for several years post diagnosis. Yet, although more of these younger individuals were receiving oral glucose-lowering agents, other cardioprotective therapies were prescribed less often in this group. Differences in BMI, blood glucose and lipid levels remained with adjustment for potential confounders, including marital status, education and country of birth, and, where relevant, differential treatments by age, and in those with at least 5 years of follow-up.

Conclusions/interpretation

Individuals who develop type 2 diabetes at a younger age are more frequently obese, display a more adverse lipid profile, have higher HbA1c and a faster deterioration in glycaemic control compared with individuals who develop diabetes later in life. These differences largely remain for several years after diagnosis and support the notion that early-onset type 2 diabetes may be a more pathogenic condition than late-onset disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference González ELM, Johansson S, Wallander M-A, Rodríguez LAG (2009) Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. J Epidemiol Community Health 63:332–336CrossRefPubMed González ELM, Johansson S, Wallander M-A, Rodríguez LAG (2009) Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. J Epidemiol Community Health 63:332–336CrossRefPubMed
2.
go back to reference Mokdad AH, Ford ES, Bowman BA et al (2000) Diabetes trends in the U.S.: 1990-1998. Diabetes Care 23:1278–1283CrossRefPubMed Mokdad AH, Ford ES, Bowman BA et al (2000) Diabetes trends in the U.S.: 1990-1998. Diabetes Care 23:1278–1283CrossRefPubMed
3.
go back to reference Alberti G, Zimmet P, Shaw J et al (2004) Type 2 diabetes in the young: the evolving epidemic: the International Diabetes Federation Consensus Workshop. Diabetes Care 27:1798–1811CrossRefPubMed Alberti G, Zimmet P, Shaw J et al (2004) Type 2 diabetes in the young: the evolving epidemic: the International Diabetes Federation Consensus Workshop. Diabetes Care 27:1798–1811CrossRefPubMed
4.
go back to reference Koopman RJ, Mainous AG, Diaz VA, Geesey ME (2005) Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann Fam Med 3:60–63CrossRefPubMedPubMedCentral Koopman RJ, Mainous AG, Diaz VA, Geesey ME (2005) Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann Fam Med 3:60–63CrossRefPubMedPubMedCentral
5.
go back to reference Grinstein G, Muzumdar R, Aponte L et al (2003) Presentation and 5-year follow-up of type 2 diabetes mellitus in African-American and Caribbean-Hispanic adolescents. Horm Res 60:121–126PubMed Grinstein G, Muzumdar R, Aponte L et al (2003) Presentation and 5-year follow-up of type 2 diabetes mellitus in African-American and Caribbean-Hispanic adolescents. Horm Res 60:121–126PubMed
6.
go back to reference Mokdad AH, Serdula MK, Dietz WH et al (1999) The spread of the obesity epidemic in the United States, 1991-1998. JAMA 282:1519–1522CrossRefPubMed Mokdad AH, Serdula MK, Dietz WH et al (1999) The spread of the obesity epidemic in the United States, 1991-1998. JAMA 282:1519–1522CrossRefPubMed
7.
go back to reference Hillier TA, Pedula KL (2003) Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care 26:2999–3005CrossRefPubMed Hillier TA, Pedula KL (2003) Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care 26:2999–3005CrossRefPubMed
8.
go back to reference Gordon-Dseagu VLZ, Shelton N, Mindell J (2014) Diabetes mellitus and mortality from all-causes, cancer, cardiovascular and respiratory disease: evidence from the Health Survey for England and Scottish Health Survey cohorts. J Diabetes Complicat 28:791–797CrossRefPubMed Gordon-Dseagu VLZ, Shelton N, Mindell J (2014) Diabetes mellitus and mortality from all-causes, cancer, cardiovascular and respiratory disease: evidence from the Health Survey for England and Scottish Health Survey cohorts. J Diabetes Complicat 28:791–797CrossRefPubMed
9.
go back to reference Jansson SPO, Andersson DKG, Svärdsudd K (2016) Mortality and cardiovascular disease outcomes among 740 patients with new-onset type 2 diabetes detected by screening or clinically diagnosed in general practice. Diabet Med 33:324–331CrossRefPubMed Jansson SPO, Andersson DKG, Svärdsudd K (2016) Mortality and cardiovascular disease outcomes among 740 patients with new-onset type 2 diabetes detected by screening or clinically diagnosed in general practice. Diabet Med 33:324–331CrossRefPubMed
10.
go back to reference Bell RA, Mayer-Davis EJ, Beyer JW et al (2009) Diabetes in non-Hispanic white youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 32(Suppl 2):S102–S111CrossRefPubMedPubMedCentral Bell RA, Mayer-Davis EJ, Beyer JW et al (2009) Diabetes in non-Hispanic white youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 32(Suppl 2):S102–S111CrossRefPubMedPubMedCentral
11.
go back to reference Eppens MC, Craig ME, Cusumano J et al (2006) Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care 29:1300–1306CrossRefPubMed Eppens MC, Craig ME, Cusumano J et al (2006) Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care 29:1300–1306CrossRefPubMed
12.
go back to reference Zeitler P, Hirst K, Pyle L et al (2012) A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 366:2247–2256CrossRefPubMed Zeitler P, Hirst K, Pyle L et al (2012) A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 366:2247–2256CrossRefPubMed
13.
go back to reference Tancredi M, Rosengren A, Svensson A-M et al (2015) Excess mortality among persons with type 2 diabetes. N Engl J Med 373:1720–1732CrossRefPubMed Tancredi M, Rosengren A, Svensson A-M et al (2015) Excess mortality among persons with type 2 diabetes. N Engl J Med 373:1720–1732CrossRefPubMed
14.
go back to reference Wong J, Constantino M, Yue DK (2015) Morbidity and mortality in young-onset type 2 diabetes in comparison to type 1 diabetes: where are we now? Curr Diab Rep 15:566CrossRefPubMed Wong J, Constantino M, Yue DK (2015) Morbidity and mortality in young-onset type 2 diabetes in comparison to type 1 diabetes: where are we now? Curr Diab Rep 15:566CrossRefPubMed
15.
go back to reference Eliasson B, Gudbjörnsdottir S (2014) Diabetes care – improvement through measurement. Diabetes Res Clin Pract 106:S291–S294CrossRefPubMed Eliasson B, Gudbjörnsdottir S (2014) Diabetes care – improvement through measurement. Diabetes Res Clin Pract 106:S291–S294CrossRefPubMed
16.
go back to reference Rawshani A, Landin-Olsson M, Svensson AM et al (2014) The incidence of diabetes among 0-34 year olds in Sweden: new data and better methods. Diabetologia 57:1375–1381CrossRefPubMedPubMedCentral Rawshani A, Landin-Olsson M, Svensson AM et al (2014) The incidence of diabetes among 0-34 year olds in Sweden: new data and better methods. Diabetologia 57:1375–1381CrossRefPubMedPubMedCentral
18.
go back to reference Hoelzel W, Weykamp C, Jeppsson JO et al (2004) IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 50:166–174CrossRefPubMed Hoelzel W, Weykamp C, Jeppsson JO et al (2004) IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 50:166–174CrossRefPubMed
19.
go back to reference Huo X, Gao L, Guo L et al (2016) Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. Lancet Diabetes Endocrinol 4:115–124CrossRefPubMed Huo X, Gao L, Guo L et al (2016) Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. Lancet Diabetes Endocrinol 4:115–124CrossRefPubMed
20.
go back to reference Wright AK, Kontopantelis E, Emsley R et al (2017) Life expectancy and cause-specific mortality in type 2 diabetes: a population-based cohort study quantifying relationships in ethnic subgroups. Diabetes Care 40:338–345CrossRefPubMed Wright AK, Kontopantelis E, Emsley R et al (2017) Life expectancy and cause-specific mortality in type 2 diabetes: a population-based cohort study quantifying relationships in ethnic subgroups. Diabetes Care 40:338–345CrossRefPubMed
21.
go back to reference Emerging Risk Factors Collaboration, SRK S, Kaptoge S et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841CrossRef Emerging Risk Factors Collaboration, SRK S, Kaptoge S et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841CrossRef
22.
go back to reference Hatunic M, Burns N, Finucane F et al (2005) Contrasting clinical and cardiovascular risk status between early and later onset type 2 diabetes. Diab Vasc Dis Res 2:73–75CrossRefPubMed Hatunic M, Burns N, Finucane F et al (2005) Contrasting clinical and cardiovascular risk status between early and later onset type 2 diabetes. Diab Vasc Dis Res 2:73–75CrossRefPubMed
23.
go back to reference Hillier TA, Pedula KL (2001) Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. Diabetes Care 24:1522–1527CrossRefPubMed Hillier TA, Pedula KL (2001) Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. Diabetes Care 24:1522–1527CrossRefPubMed
24.
go back to reference Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412CrossRefPubMedPubMedCentral Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412CrossRefPubMedPubMedCentral
25.
go back to reference Niskanen L, Turpeinen A, Penttilä I, Uusitupa MIJ (1998) Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care 21:1861–1869CrossRefPubMed Niskanen L, Turpeinen A, Penttilä I, Uusitupa MIJ (1998) Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care 21:1861–1869CrossRefPubMed
26.
go back to reference Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ et al (2002) Prevalence and characteristics of early-onset type 2 diabetes in Mexico. Am J Med 113:569–574CrossRefPubMed Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ et al (2002) Prevalence and characteristics of early-onset type 2 diabetes in Mexico. Am J Med 113:569–574CrossRefPubMed
27.
go back to reference Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS et al (2010) Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375:1634–1639CrossRefPubMedCentral Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS et al (2010) Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375:1634–1639CrossRefPubMedCentral
28.
go back to reference Navar-Boggan AM, Peterson ED, D’Agostino RB et al (2015) Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation 131:451–458CrossRefPubMedPubMedCentral Navar-Boggan AM, Peterson ED, D’Agostino RB et al (2015) Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation 131:451–458CrossRefPubMedPubMedCentral
29.
go back to reference JBS3 Board (2014) Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 100:ii1-ii67 JBS3 Board (2014) Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 100:ii1-ii67
30.
go back to reference Song SH, Hardisty CA (2009) Early onset type 2 diabetes mellitus: a harbinger for complications in later years – clinical observation from a secondary care cohort. QJM 102:799–806CrossRefPubMed Song SH, Hardisty CA (2009) Early onset type 2 diabetes mellitus: a harbinger for complications in later years – clinical observation from a secondary care cohort. QJM 102:799–806CrossRefPubMed
31.
go back to reference Sniderman AD, Thanassoulis G, Williams K, Pencina M (2016) Risk of premature cardiovascular disease vs the number of premature cardiovascular events. JAMA Cardiol 1:492–494CrossRefPubMed Sniderman AD, Thanassoulis G, Williams K, Pencina M (2016) Risk of premature cardiovascular disease vs the number of premature cardiovascular events. JAMA Cardiol 1:492–494CrossRefPubMed
32.
Metadata
Title
Short-term progression of cardiometabolic risk factors in relation to age at type 2 diabetes diagnosis: a longitudinal observational study of 100,606 individuals from the Swedish National Diabetes Register
Authors
Andri O. Steinarsson
Araz Rawshani
Soffia Gudbjörnsdottir
Stefan Franzén
Ann-Marie Svensson
Naveed Sattar
Publication date
01-03-2018
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 3/2018
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-017-4532-8

Other articles of this Issue 3/2018

Diabetologia 3/2018 Go to the issue

Up front

Up front

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.